Ertugliflozin/sitagliptin

Drug Profile

Ertugliflozin/sitagliptin

Alternative Names: MK 8835/MK 0431; MK 8835A

Latest Information Update: 07 Mar 2017

Price : $50

At a glance

  • Originator Merck & Co; Pfizer
  • Class Antihyperglycaemics; Chlorobenzenes; Glycosides; Heterocyclic bicyclo compounds; Phenyl ethers; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action CD26 antigen inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus

Most Recent Events

  • 06 Mar 2017 Preregistration for Type-2 diabetes mellitus (Monotherapy) in USA (PO)
  • 06 Mar 2017 Preregistration for Type-2 diabetes mellitus in European Union (PO)
  • 06 Mar 2017 The US FDA sets PDUFA date of December 2017 for NDA review for Type II diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top